FDA keeps boxed warning about suicide on Chantix

The Food and Drug Administration is keeping a bold-letter warning on Pfizer’s anti-smoking drug Chantix about suicidal behavior and other psychiatric side effects, after reviewing company findings suggesting the drug does not increase those problems. The twice-a-day tablet has carried the FDA’s strongest warning label since 2009, following reports of suicidal tendencies and violent or bizarre behavior among some patients.